nivolumab,ipilimumab,celecoxib
bms
['gicsm', 'ipilimumab', 'nivo', 'nivolumab', '#gi']
patients with mismatch repair deficient (dmmr) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks. #gicsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.